10-QPeriod: Q3 FY2016

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2016

Filed November 1, 2016For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2016, with total revenue increasing by 10.8% to $1.33 billion. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw a 12.0% revenue increase, highlighting sustained demand for veterinary diagnostics and services. Net income attributable to stockholders rose significantly to $169.7 million, up from $147.7 million in the prior year period, demonstrating improved profitability. The company also maintained a healthy cash flow from operations, providing flexibility for strategic investments and shareholder returns. The company's balance sheet reflects a solid financial position, with total assets growing and liabilities decreasing, leading to a substantial improvement in stockholders' equity. Cash and cash equivalents increased, bolstered by strong operating performance. IDEXX continues to manage its debt effectively, with a favorable debt-to-EBITDA ratio, indicating sound financial management and ample liquidity for ongoing operations and future growth initiatives.

Financial Statements
Beta

Key Highlights

  • 1Total revenue for the nine months ended September 30, 2016, increased by 10.8% to $1.33 billion, compared to $1.20 billion in the prior year period.
  • 2Net income attributable to IDEXX Laboratories, Inc. stockholders increased to $169.7 million for the nine months ended September 30, 2016, from $147.7 million in the prior year period.
  • 3The Companion Animal Group (CAG) segment remains the primary growth driver, with revenue increasing by 12.0% to $1.14 billion for the nine months ended September 30, 2016.
  • 4Operating cash flow for the nine months ended September 30, 2016, was robust at $234.5 million, a significant increase from $142.5 million in the prior year period.
  • 5Total assets grew to $1.50 billion as of September 30, 2016, from $1.47 billion as of December 31, 2015, while total liabilities decreased from $1.56 billion to $1.45 billion.
  • 6The company's effective income tax rate remained stable at approximately 30.7% for the nine months ended September 30, 2016.
  • 7IDEXX continues to return value to shareholders, with share repurchases moderating in the current period compared to the prior year, alongside maintaining a strong debt leverage ratio.

Frequently Asked Questions

For the nine months ended September 30, 2016, IDEXX reported a 10.8% increase in total revenue to $1.33 billion. The Companion Animal Group (CAG) segment was the primary driver of this growth, with a 12.0% revenue increase to $1.14 billion, highlighting the continued strong performance in veterinary diagnostics and services.

Profitability improved significantly. Net income attributable to IDEXX Laboratories, Inc. stockholders for the nine months ended September 30, 2016, was $169.7 million, an increase from $147.7 million in the same period of the prior year. This indicates strong operational efficiency and revenue growth translating into higher net earnings.

IDEXX demonstrated strong operating cash flow, generating $234.5 million for the nine months ended September 30, 2016, up from $142.5 million in the prior year. The company also maintained a healthy financial position with a debt-to-Adjusted EBITDA ratio of 1.61 as of September 30, 2016, indicating prudent debt management and ample borrowing capacity.

The company recorded non-cash intangible asset impairments of $2.2 million related to its OPTI Medical line of business during the nine months ended September 30, 2016, due to a change in strategy. Additionally, there was an $8.2 million impairment charge in the third quarter of 2015 for internally-developed software that was not placed into service. These were disclosed within the 'Unallocated Amounts' or specific segment details.